compounded semaglutide glp-1 injections Hims & Hers stock falls 25% as FDA curtails GLP-1s Switching from a compounded to
Description
doi: 10.1097/MCO.0000000000001130
An important note: semaglutide may interfere with B12 assay results, potentially leading to false low readings when used alongside metformin
Spatially resolved multiomics of human cardiac niches
That is, investigations are warranted to better understand the potential benefit of combined use of GLP-1 RAs and SGLT2 inhibitors in HF with specific focus on the sequence of treatment initiation and the suitable population, including by HF phenotype and presence of diabetes
